VIR Vir Biotechnology, Inc.
$11.57▲ +4.80%
Healthcare
Other
After hours
$11.77▲ +1.73%
Oct 27, 4:53 PM ET
Volume 1.97M
Avg Volume (10D) 1.58M
Key Metrics & Fundamentals
Market Cap
$1.96B
P/E Ratio
–
Div Yield
0.00%
52W Range
4.82 - 12.00
% vs 50 MA
6.99%
% vs 200 MA
22.55%
RSI-14
59.1
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.73
Free Cash Flow
$123.29M
Gross Rev
$238.94M
Gross Profit
$238.94M
EBITDA
$77.99M
COGS
$0
Operating Exp
$165.47M
Operating Income
$73.47M
EBIT
$73.47M
Pretax Income
$80.26M
Net Income
$80.08M
EPS (Diluted)
0.47
Price & Volume History
Loading chart…
Recent News
Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?
Simply Wall St. · Oct 26, 2026 8:19 PM ET
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Business Wire · Oct 21, 2026 4:05 PM ET
Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?
Simply Wall St. · Oct 17, 2026 7:10 AM ET
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Stocktwits · Oct 16, 2026 7:57 PM ET
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Zacks · Oct 15, 2026 1:17 PM ET
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
Pharmaceutical Technology · Oct 15, 2026 10:30 AM ET
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership?
Simply Wall St. · Oct 14, 2026 1:09 PM ET
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
MT Newswires · Oct 14, 2026 9:22 AM ET
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Business Wire · Oct 14, 2026 8:30 AM ET
Sector Update: Healthcare
MT Newswires · Oct 9, 2026 1:18 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VIR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.